Pages that link to "Q33372690"
Jump to navigation
Jump to search
The following pages link to Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. (Q33372690):
Displaying 50 items.
- Targeting the tumor microenvironment: JAK-STAT3 signaling (Q26825658) (← links)
- Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets (Q27024482) (← links)
- 14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells (Q27310406) (← links)
- MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma (Q28552305) (← links)
- Therapeutic modulators of STAT signalling for human diseases (Q33684732) (← links)
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. (Q33697369) (← links)
- β-Actin is a downstream effector of the PI3K/AKT signaling pathway in myeloma cells (Q33744159) (← links)
- CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy (Q33904846) (← links)
- A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation (Q33934987) (← links)
- Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways (Q33984585) (← links)
- Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. (Q34194704) (← links)
- The transcriptional modulator BCL6 as a molecular target for breast cancer therapy (Q34245186) (← links)
- STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes (Q34518047) (← links)
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors (Q34754412) (← links)
- STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers (Q34796500) (← links)
- Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies (Q35132241) (← links)
- Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells (Q35165105) (← links)
- Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model (Q35274726) (← links)
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival (Q35551777) (← links)
- Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. (Q35591909) (← links)
- Targeting the interleukin-6/Jak/stat pathway in human malignancies (Q35925127) (← links)
- Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. (Q36350751) (← links)
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations (Q36481950) (← links)
- Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma (Q36528249) (← links)
- NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations (Q36645788) (← links)
- A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway (Q36962588) (← links)
- TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity (Q37007610) (← links)
- STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. (Q37036322) (← links)
- Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer (Q37068166) (← links)
- NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways (Q37268717) (← links)
- Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. (Q37309060) (← links)
- Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP (Q37411232) (← links)
- Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation (Q37603497) (← links)
- Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis (Q37744890) (← links)
- Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. (Q37745238) (← links)
- Cancer-associated myeloproliferation: old association, new therapeutic target (Q37769017) (← links)
- Overview of the Generation, Validation, and Application of Phosphosite-Specific Antibodies (Q37849220) (← links)
- Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy (Q37869903) (← links)
- STAT signaling in the pathogenesis and treatment of myeloid malignancies (Q38140880) (← links)
- The current management of brain metastasis in melanoma: a focus on riluzole (Q38532696) (← links)
- STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents (Q38533925) (← links)
- STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy (Q38667977) (← links)
- Growth inhibitory effect of β-eudesmol on cholangiocarcinoma cells and its potential suppressive effect on heme oxygenase-1 production, STAT1/3 activation, and NF-κB downregulation (Q38696642) (← links)
- Cyclophilin A as a downstream effector of PI3K/Akt signalling pathway in multiple myeloma cells (Q38797470) (← links)
- Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. (Q39033624) (← links)
- Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. (Q39120515) (← links)
- STAT3 activation in infection and infection-associated cancer (Q39145689) (← links)
- QUICK identification and SPR validation of signal transducers and activators of transcription 3 (Stat3) interacting proteins (Q39444864) (← links)
- Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (Q39571840) (← links)
- Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling (Q39669883) (← links)